


PHARMACEUTICAL 2019

Arcturus Therapeutics Ltd. Rank 211 of 371





PHARMACEUTICAL 2019

Arcturus Therapeutics Ltd. Rank 211 of 371

The relative strengths and weaknesses of Arcturus Therapeutics Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcturus Therapeutics Ltd. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Arcturus Therapeutics Ltd. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 74% points.

The company's Economic Capital Ratio, given in the ranking table, is -196%, being 135% points above the market average of -331%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 41,828 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 12,577 |
| Liabilities, Non-Current | 9,911 |
| Other Assets | 395 |
| Other Compr. Net Income | 3.0 |
| Other Expenses | 0 |
| Other Liabilities | 8,068 |
| Other Net Income | 26 |
| Property and Equipment | 1,975 |
| Research and Development | 16,982 |
| Revenues | 15,753 |
| Selling, General and Administrative Expense | 20,582 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 44,198 |
| Liabilities | 30,556 |
| Expenses | 37,564 |
| Stockholders Equity | 13,642 |
| Net Income | -21,785 |
| Comprehensive Net Income | -21,784 |
| Economic Capital Ratio | -196% |